证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－082 华润双鹤药业股份有限公司 关于全资子公司安徽双鹤药业有限责任公司 盐酸替罗非班氯化钠注射液获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公司 安徽双鹤药业有限责任公司(以下简称"安徽双鹤")收到了国家药品监 督管理局(以下简称"国家药监局")颁发的盐酸替罗非班氯化钠注射液 (以下简称"该药品")《药品注册证书》。现将相关情况公告如下： 一、药品注册证书主要内容 | 药品名称 | 药品通用名称：盐酸替罗非班氯化钠注射液 英文名/拉丁名：Tirofiban Hydrochloride and Sodium | | --- | --- | | | Chloride Injection | | 剂型 | 注射剂 | | 注册分类 | 化学药品 类 3 | | | 100ml:盐酸替罗非班(按C22H36N2O5S计)5mg与氯化 钠0.9g； | | 规格 | 250ml:盐酸 ...

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its wholly-owned subsidiary, Anhui Double Crane, received a drug registration certificate from the National Medical Products Administration for the sodium chloride injection of Ticagrelor, which is an antiplatelet aggregation drug used for preventing early myocardial infarction in adult patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) [1] Company Summary - The drug is specifically indicated for adult patients experiencing chest pain within 12 hours and accompanied by ECG changes and/or elevated myocardial enzymes [1]

Core Viewpoint - China Resources Double Crane announced that its wholly-owned subsidiary, Anhui Double Crane Pharmaceutical Co., Ltd., has received the drug registration certificate for Sodium Chloride Injection of Tirofiban Hydrochloride from the National Medical Products Administration, which is considered equivalent to passing the consistency evaluation [1] Summary by Category - **Regulatory Approval** - The company has obtained the drug registration certificate for Sodium Chloride Injection of Tirofiban Hydrochloride, indicating compliance with national regulations [1] - **Research and Development Investment** - The total R&D investment for this drug has reached 3.7558 million RMB (approximately 0.37558 million) as of the date of the announcement [1]

Core Viewpoint - China Resources Double Crane Pharmaceutical Co., Ltd. has received a drug registration certificate from the National Medical Products Administration for its sodium chloride injection of tirofiban hydrochloride, indicating a significant advancement in its product portfolio [1] Group 1: Company Developments - The wholly-owned subsidiary Anhui Double Crane Pharmaceutical Co., Ltd. is responsible for the newly approved drug [1] - The drug is indicated for adult patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) who experience chest pain within 12 hours and have ECG changes and/or elevated myocardial enzymes [1] - The drug is also used for patients with ST-segment elevation myocardial infarction (STEMI) undergoing planned direct percutaneous coronary intervention (PCI) to reduce the occurrence of major cardiovascular events [1]

Group 1 - China Shipbuilding has completed the share swap absorption merger with China Shipbuilding Industry Corporation, with 3.053 billion new shares listed on September 16, 2025 [1] - Transsion Holdings' shareholder plans to transfer 2% of the company's shares, amounting to approximately 22.807 million shares [1] Group 2 - Chipone Technology reported a record high in new orders from July 1 to September 11, 2025, totaling 1.205 billion yuan, with AI computing orders accounting for about 64% [2] - Chipone Technology's total order amount reached 3.025 billion yuan by the end of the second quarter of 2025, indicating a significant increase [2] Group 3 - Chipone Technology plans to acquire 97.0070% equity of Chipai Technology through a combination of share issuance and cash payment, with the stock resuming trading on September 12 [3] Group 4 - Xinjun Network received a notice of share reduction from its major shareholder, Shanghai Senxiao Investment Center, which reduced its holdings by 1.6271 million shares, bringing its ownership down to 5.29% [4] Group 5 - Yangjie Technology intends to acquire 100% equity of Better Electronics for 2.218 billion yuan, with a profit commitment of no less than 555 million yuan from 2025 to 2027 [5] Group 6 - Shoukai Co. announced that its subsidiary, Yingxin Company, indirectly holds approximately 0.3% equity in Yushu Technology, indicating a low ownership stake [6] Group 7 - Xiamen Airport reported a total passenger throughput of 2.707 million in August, representing a year-on-year increase of 5.18% [9] - *ST Tianshan experienced a significant decline in livestock sales revenue, down 95.80% year-on-year in August [9] Group 8 - Taihe Intelligent's shareholder plans to transfer 5.79% of the company's shares to Sunshine New Energy [9] - Jilin Expressway's subsidiary won a construction project worth 9.592 billion yuan [9] - Tianyong Intelligent secured a project with SAIC Group for engine assembly line renovation [9]

Core Viewpoint - China Resources Double Crane (华润双鹤) announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. (上海长征富民金山制药有限公司), has received the approval notice from the National Medical Products Administration for the supplementary application of peritoneal dialysis solution (Lactate-G1.5%) and peritoneal dialysis solution (Lactate-G2.5%) [1] Company Summary - The approval pertains to two specific products related to peritoneal dialysis, indicating a potential expansion in the company's product offerings in the medical field [1] - This development may enhance the company's market position in the healthcare sector, particularly in renal care solutions [1]

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－081 华润双鹤药业股份有限公司 关于全资子公司上海长征富民金山制药有限公司 腹膜透析液(乳酸盐)系列药品获得 药品补充申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完 整性承担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公 司上海长征富民金山制药有限公司(以下简称"上海长富")收到了国 家药品监督管理局(以下简称"国家药监局")颁发的腹膜透析液(乳酸 盐-G1.5%)、腹膜透析液(乳酸盐-G2.5%)(以下简称"该系列药品") 《药品补充申请批准通知书》。现将相关情况公告如下： 一、通知书主要内容 | 药品名称 | 药品通用名称： 腹膜透析液(乳酸盐-G1.5%) | 英文名/拉丁名： | | --- | --- | --- | | | 腹膜透析液(乳酸盐-G2.5%) | PeritonealDialysisSolution(Lactate-G1.5%) PeritonealDialysisSolution(Lactate-G2. ...

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co., Ltd. (referred to as "Shanghai Changfu"), has received the approval notice for the supplementary application of peritoneal dialysis solution (lactate-G1.5%) and peritoneal dialysis solution (lactate-G2.5%) from the National Medical Products Administration (NMPA) [1] Group 1 - The peritoneal dialysis solution (lactate) is primarily used for patients with acute and chronic renal failure who require continuous non-bedside peritoneal dialysis treatment due to ineffective non-dialysis therapy [1] - The approval of the supplementary application for the peritoneal dialysis solution (lactate) represents an enhancement of the product specifications, which is expected to benefit the future market sales and competitive potential of this product series [1]

Core Viewpoint - China Resources Double Crane (600062.SH) announced that its wholly-owned subsidiary, Shanghai Changzheng Fumin Jinsan Pharmaceutical Co., Ltd. (referred to as "Shanghai Changfu"), received the Drug Supplement Application Approval Notice from the National Medical Products Administration for peritoneal dialysis solutions (lactate-G1.5% and lactate-G2.5%) [1] Group 1 - The peritoneal dialysis solutions (lactate) are primarily suitable for patients with acute and chronic renal failure who require continuous non-bedside peritoneal dialysis treatment due to ineffective non-dialysis therapy [1] - The approval of the Drug Supplement Application is a further enhancement of the specifications for the peritoneal dialysis solutions (lactate), which will benefit the future market sales and competitive potential of this product series [1]

Group 1 - The core point of the article is that China Resources Double Crane has received approval from the National Medical Products Administration for its peritoneal dialysis solution, indicating a significant development in its product portfolio [1] - The peritoneal dialysis solution is primarily used for patients with acute and chronic renal failure, highlighting the company's focus on critical healthcare needs [1] - The company has invested a total of 1.2174 million yuan in research and development for this product, reflecting its commitment to innovation in the pharmaceutical sector [1] Group 2 - The global market size for peritoneal dialysis solutions (lactate) is projected to be approximately 5.62 billion USD in 2024, indicating a substantial market opportunity [1] - The domestic sales total for peritoneal dialysis solutions is estimated at 2.78 billion yuan, showcasing the potential for growth in the local market [1] - China Resources Double Crane's sales revenue from this product line is reported at 317 million yuan, capturing a market share of 14%, which positions the company competitively within the industry [1]